CH 223191: Aryl Hydrocarbon Receptor Antagonist in ISC Research

Understanding the Principle: CH 223191 and AhR Pathway Inhibition

CH 223191 is a potent, selective aryl hydrocarbon receptor (AhR) antagonist, widely adopted for dissecting the mechanistic underpinnings of AhR-mediated signaling in both environmental toxicology and regenerative medicine models. By competitively inhibiting ligand-induced AhR activation, CH 223191 allows researchers to probe downstream effects on transcriptional networks, such as modulation of cytochrome P450 1A1 (CYP1A1) expression and the cellular response to environmental dioxins like TCDD (source: product_spec).

In the context of intestinal biology and mucosal repair, AhR has emerged as a central node linking microbial metabolism of tryptophan to intestinal stem cell (ISC) fate decisions. The recent study by Li et al. (2026) illuminated how pharmacological AhR inhibition with CH 223191 can rigorously validate the causal role of this pathway in driving ISC differentiation and epithelial regeneration, particularly within models of ulcerative colitis (source: Li et al. (2026)).

Step-by-Step Workflow: Optimized Use of CH 223191

Deploying CH 223191 in complex in vitro or in vivo systems demands careful attention to solubility, dosing, and timing to achieve robust, reproducible pathway inhibition. Below is an optimized workflow, integrating both manufacturer guidance and literature-backed insights:

1. Stock Preparation: Dissolve CH 223191 in DMSO to a concentration of 33.3 mg/mL for maximal solubility. If using ethanol, a maximum of 2.31 mg/mL is achievable. Avoid aqueous solvents due to insolubility (source: product_spec).
2. Aliquoting and Storage: Prepare single-use aliquots, store at -20°C, and minimize freeze-thaw cycles. Solutions are best used immediately after preparation to preserve compound integrity (source: product_spec).
3. In Vitro Assays: For cell-based inhibition of AhR activation (e.g., CYP1A1 promoter-driven luciferase), typical working concentrations range from 10–100 nM, with an IC50 of approximately 30 nM against TCDD-stimulated AhR activity (source: product_spec). Pre-incubate cells with CH 223191 for 30–60 minutes prior to agonist addition to ensure target inhibition (workflow_recommendation).
4. In Vivo Applications: In murine models, CH 223191 can be administered via intraperitoneal injection, with reference dosing guided by prior studies—e.g., 10 mg/kg/day to block TCDD-induced hepatic toxicity or to dissect the microbiota–tryptophan–AhR–ISC axis (source: Li et al. (2026)).
5. Downstream Readouts: Quantify AhR pathway activity by measuring CYP1A1 expression (qPCR, Western blot), IL-22 secretion (ELISA), and ISC lineage markers (immunofluorescence for Lgr5, MUC2, LYZ, ChgA) (source: Li et al. (2026)).

Protocol Parameters

• cell-based AhR antagonist assay | 30 nM CH 223191 | TCDD-induced AhR activation in human or mouse cell lines | Matches reported IC50 for effective AhR inhibition | product_spec
• in vivo murine dosing | 10 mg/kg/day, intraperitoneal | Blocking AhR signaling in colitis or dioxin toxicity models | Mirrors effective dose for pathway suppression and physiological readouts | Li et al. (2026)
• compound solubilization | 33.3 mg/mL in DMSO, 2.31 mg/mL in ethanol | Stock preparation for in vitro/in vivo use | Ensures maximal solubility and delivery consistency | product_spec

Key Innovation from the Reference Study

The Li et al. (2026) study is a milestone in translational mucosal biology, demonstrating for the first time that targeted AhR inhibition with CH 223191 can effectively block the pro-differentiation and regenerative effects of microbiota-driven tryptophan metabolites in ulcerative colitis models (source: Li et al. (2026)). The authors combined metagenomics, targeted metabolomics, and molecular phenotyping to confirm that:

• HQD treatment increases microbiota-derived indole metabolites, which act as AhR agonists to drive ISC differentiation.
• CH 223191 administration abolishes these effects, validating the centrality of AhR in the microbiota–tryptophan–ISC axis.

For experimentalists, this means that using CH 223191 is not only a control for AhR pathway specificity, but also a mechanistic probe for untangling host–microbe–metabolite interactions governing tissue repair. Incorporating CH 223191 in parallel with microbiota manipulations or dietary interventions provides a rigorous framework for causality testing in intestinal and systemic models.

Advanced Applications and Comparative Advantages

CH 223191 distinguishes itself from earlier AhR antagonists by its high selectivity and nanomolar potency, minimizing off-target effects that can confound data interpretation (source: perospironekits.com). In environmental toxicology, it enables precise modeling of dioxin toxicity mechanisms, as evidenced by robust suppression of CYP1A1 induction and mitigation of TCDD-induced hepatic injury markers (source: product_spec).

In regenerative medicine and stem cell biology, CH 223191 is now established as a gold-standard AhR signaling pathway inhibitor for:

• Dissecting the role of microbial metabolites and dietary components in ISC fate decisions.
• Testing the functional contributions of AhR in tissue repair, immune modulation, and homeostasis.
• Benchmarking new drug candidates or natural products for AhR-dependent mechanism-of-action.

This compound’s utility is further expanded in systems biology research, where it acts as a molecular switch for pathway validation across multiple tissues and disease models (source: balaglitazone.com).

Article Interlinking

• "CH 223191: Aryl Hydrocarbon Receptor Antagonist for AhR Pathway Dissection" complements this workflow by offering in-depth protocol troubleshooting and practical advice for maximizing inhibitor performance in complex models.
• "CH 223191 as an Aryl Hydrocarbon Receptor Antagonist: Applied Workflows" extends the discussion to highlight CH 223191’s role in regenerative medicine and its integration with stem cell differentiation assays.
• "CH 223191: Unraveling AhR Antagonism in Microbiota–Host Interplay" further explores the compound’s value in dissecting host–microbe signaling, building directly on the reference study’s mechanistic findings.

Troubleshooting & Optimization Tips

• Solubility & Precipitation: Always dissolve CH 223191 in DMSO prior to dilution in assay media. Avoid direct addition to aqueous buffers, as insolubility can lead to precipitation and reduced bioavailability (source: product_spec).
• Batch-to-Batch Consistency: Source CH 223191 from a trusted supplier such as APExBIO to ensure >98% purity and reliable performance in both in vitro and in vivo contexts (source: product_spec).
• Timing and Duration: For acute pathway inhibition, pre-treat cells or animals 30–60 min ahead of agonist or challenge. For chronic models, monitor for potential compensatory pathway activation and adjust dosing schedules accordingly (workflow_recommendation).
• Negative Controls: Always include vehicle controls (DMSO or ethanol), and where possible, complement studies with genetic AhR knockdown/knockout for orthogonal validation (workflow_recommendation).
• Readout Sensitivity: Use highly sensitive downstream assays (e.g., qPCR, ELISA) to capture subtle pathway modulation, especially at lower antagonist doses (workflow_recommendation).

Future Outlook: From Environmental Toxicology to Regenerative Medicine

As the landscape of AhR biology expands, CH 223191 stands as a pivotal tool for both foundational research and translational discovery. The insights from Li et al. (2026) not only validate the microbiota–tryptophan–AhR–ISC differentiation axis in intestinal repair, but also underscore the broader utility of precise AhR inhibition in deciphering host–microbe–environment interactions (source: Li et al. (2026)).

Looking forward, the compound’s high specificity and robust performance profile position it as a reference standard in environmental toxicology, metabolic disease, and regenerative assays. Its integration into multiplexed readouts, microbiome manipulation experiments, and preclinical disease models will continue to accelerate mechanistic discovery and therapeutic innovation.

For detailed product information and validated workflows, consult the CH 223191 product page at APExBIO.